ARTBIO Strengthens Leadership with New Board Appointments to Advance Alpha Radioligand Therapies

ARTBIO, Inc., a clinical-stage radiopharmaceutical company, has announced the addition of four distinguished professionals to its Board of Directors, marking a significant step in its mission to develop alpha radioligand therapies (ARTs) for cancer. The new appointments include Maha Katabi, Ph.D., CFA, Robert Mittendorff, M.D., MBA, Julie O’Neill, MBA, and Gabe Gelman, each bringing a wealth of experience in biotech investments, healthcare strategy, and pharmaceutical operations. These strategic additions are poised to guide ARTBIO through its next phase of growth, particularly following its recent Series B funding round.

The transition of co-founder Roy Larsen, Ph.D., from the Board of Directors to a newly established Technical Advisory Board underscores ARTBIO's commitment to leveraging deep scientific expertise in radiopharmaceuticals. Dr. Larsen's pioneering work in the field has been instrumental in ARTBIO's foundation and will continue to influence the company's innovative approaches to cancer therapy. Ted W. Love, M.D., Chairman of the Board at ARTBIO, emphasized the value of the new board members' insights in advancing the company's programs designed to make a significant impact on patient care.

ARTBIO's focus on developing a new class of 212Pb alpha radioligand therapies is supported by its AlphaDirect technology, a groundbreaking method for the isolation of Pb212, enabling a distributed manufacturing approach. This technology is central to ARTBIO's lead program, AB001, currently in first-in-human trials for metastatic castration-resistant prostate cancer. The company's efforts are rooted in a long-standing scientific legacy, with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital.

For more information on ARTBIO and its innovative cancer therapies, visit https://www.artbio.com. The strategic enhancements to ARTBIO's leadership and advisory boards signal a robust future for the development of alpha radioligand therapies, offering new hope for cancer patients worldwide.